Online first articles
Articles not assigned to an issue 47 articles
-
-
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy
Authors (first, second and last of 12)
- Atsushi Ogawa
- Hiroshi Kawamoto
- Toshimi Kimura
- Content type: Original Article
- Open Access
- Published: 13 March 2024
-
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment
Authors (first, second and last of 7)
- Nancy H.C. Loos
- Viët Bui
- Alfred H. Schinkel
- Content type: Original Article
- Published: 08 March 2024
-
Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series
Authors (first, second and last of 12)
- Takashi Masuda
- Taro Funakoshi
- Atsushi Yonezawa
- Content type: Case Report
- Published: 08 March 2024
-
Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer
Authors (first, second and last of 8)
- Wei Zheng
- Wei Peng
- Xiaoying Fu
- Content type: Original Article
- Published: 08 March 2024
-
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer
Authors (first, second and last of 6)
- Koutaro Ono
- Remi Murase
- Ken-ichi Fujita
- Content type: Original Article
- Published: 08 March 2024
-
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer
Authors (first, second and last of 5)
- Guangnan Zong
- Jinlin Li
- Xiuli Guo
- Content type: Short Communication
- Published: 07 March 2024
-
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
Authors (first, second and last of 10)
- Colby S. Shemesh
- Yongsheng Wang
- Xian Wang
- Content type: Original Article
- Open Access
- Published: 07 March 2024
-
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants
Authors (first, second and last of 8)
- Romain Sechaud
- Helen Gu
- Hans D. Menssen
- Content type: Correction
- Published: 05 March 2024
-
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients
Authors (first, second and last of 7)
- Jaya Shree Dilli Batcha
- Vikram Gota
- Surulivelrajan Mallayasamy
- Content type: Original Article
- Open Access
- Published: 05 March 2024
-
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors
Authors (first, second and last of 7)
- Kadriye Bir Yücel
- Uguray Aydos
- Ozan Yazıcı
- Content type: Original Article
- Published: 04 March 2024
-
Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia
Authors (first, second and last of 9)
- Wenqiang Qu
- Jialing Lu
- Suning Chen
- Content type: Short Communication
- Published: 02 March 2024
-
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy
Authors
- Yan Ji
- Sherwin K. B. Sy
- Content type: Review Article
- Published: 02 March 2024
-
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data
Authors (first, second and last of 9)
- Cedric Lau
- Ma Ida Mohmaed Ali
- Alwin D. R. Huitema
- Content type: Original Article
- Open Access
- Published: 01 March 2024
-
Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children’s Research Hospital
Authors (first, second and last of 9)
- Alyssa Gaietto
- John C Panetta
- Hope D Swanson
- Content type: Original Article
- Published: 28 February 2024
-
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Authors (first, second and last of 14)
- Toshihiko Doi
- Shunji Takahashi
- Shinichi Okame
- Content type: Original Article
- Open Access
- Published: 27 February 2024
-
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype
Authors
- John F. Marcelletti
- Branimir I. Sikic
- Content type: Original Article
- Published: 26 February 2024
-
Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab
Authors (first, second and last of 4)
- Zhuoyuan Yu
- Haifan Xu
- Liqun Chen
- Content type: Original Article
- Published: 25 February 2024
-
18β-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis
Authors (first, second and last of 9)
- Xuan Ma
- Zhenou Sun
- Hongbo Hu
- Content type: Original Article
- Published: 21 February 2024
-
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001)
Authors (first, second and last of 20)
- Mayumi Ozawa
- Jun Watanabe
- Itaru Endo
- Content type: Original Article
- Published: 19 February 2024
-
Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study
Authors (first, second and last of 9)
- Andrea René Jørgensen
- Mats Bue
- Maiken Stilling
- Content type: Original Article
- Open Access
- Published: 08 February 2024
-
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study
Authors (first, second and last of 7)
- Ahmed O. ELKasar
- Fatma Z. Hussien
- Adel R. Abd-Allah
- Content type: Original Article
- Published: 07 February 2024
-
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure
Authors (first, second and last of 10)
- Vikram Malhi
- Malgorzata Nowicka
- Jiajie Yu
- Content type: Short Communication
- Open Access
- Published: 02 February 2024
-
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations
Authors (first, second and last of 10)
- Xiaoya Ma
- Yujie Li
- Tianbo Jin
- Content type: Original Article
- Published: 01 February 2024
-
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
Authors (first, second and last of 10)
- Bin Fan
- Ghassan K. Abou-Alfa
- Hua Yang
- Content type: Original Article
- Open Access
- Published: 27 January 2024
-
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells
Authors (first, second and last of 10)
- Alexandr N. Chernov
- Alexandr V. Kim
- Olga V. Shamova
- Content type: Original Article
- Published: 27 January 2024
-
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants
Authors (first, second and last of 8)
- Romain Sechaud
- Helen Gu
- Hans D. Menssen
- Content type: Original Article
- Published: 25 January 2024
-
Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity
Authors (first, second and last of 7)
- Qian Tan
- A. M. Joshua
- Ian F. Tannock
- Content type: Correction
- Published: 19 January 2024
-
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells
Authors (first, second and last of 8)
- Thamir M. Mahgoub
- Emmet J. Jordan
- Denis M. Collins
- Content type: Original Article
- Open Access
- Published: 16 January 2024
-
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
Authors (first, second and last of 12)
- Noboru Yamamoto
- Takafumi Koyama
- Toshio Shimizu
- Content type: Short Communication
- Open Access
- Published: 11 January 2024
-
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation
Authors (first, second and last of 13)
- Chong-Zhi Wang
- Chunping Wan
- Chun-Su Yuan
- Content type: Original Article
- Published: 09 January 2024
-
Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy
Authors
- Feng Yu
- Hongjie Huo
- Qiong Tang
- Content type: Original Article
- Open Access
- Published: 04 January 2024
-
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report
Authors (first, second and last of 5)
- Yoshiharu Suzuki
- Shingo Ishiguro
- Mika Suzuki
- Content type: Short Communication
- Published: 26 December 2023
-
Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins
Authors (first, second and last of 12)
- Junquan Zeng
- Yongliang Zheng
- Tingting Liu
- Content type: Original Article
- Open Access
- Published: 26 December 2023
-
Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule
Authors (first, second and last of 5)
- Shinji Kobuchi
- Atsuko Morita
- Yukako Ito
- Content type: Original Article
- Published: 20 December 2023
-
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients
Authors (first, second and last of 8)
- K. Westerdijk
- S. D. Krens
- N. P. van Erp
- Content type: Original Article
- Open Access
- Published: 17 December 2023
-
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
Authors (first, second and last of 10)
- Nobuaki Matsubara
- Shota Kusuhara
- Toshio Shimizu
- Content type: Original Article
- Open Access
- Published: 13 December 2023
-
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study
Authors (first, second and last of 11)
- Carla Biesdorf
- Xiaowen Guan
- Akshanth R. Polepally
- Content type: Original Article
- Published: 30 November 2023
-
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study
Authors (first, second and last of 8)
- Hiroaki Takahashi
- Yoko Saito
- Kenzo Kudo
- Content type: Original Article
- Published: 28 November 2023
-
Azithromycin in cancer treatment: envisioning the probable link of mitochondrial dysfunction and necroptosis
Authors
- Siti Nazihahasma Hassan
- Farizan Ahmad
- Content type: Letter to the Editor
- Published: 14 November 2023
-
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?
Authors (first, second and last of 9)
- Mourad Hamimed
- Raynier Devillier
- Samia Harbi
- Content type: Short Communication
- Published: 13 November 2023
-
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults
Authors (first, second and last of 13)
- Yizhe Chen
- David Wyatt
- Gopal Krishna
- Content type: Original Article
- Open Access
- Published: 13 November 2023
-
CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms
Authors (first, second and last of 9)
- Yuanpei Wang
- Jing Wen
- Fang Ren
- Content type: Original Article
- Published: 08 November 2023
-
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report
Authors (first, second and last of 6)
- M. Berge
- J. S. Giraud
- B. Blanchet
- Content type: Letter to the Editor
- Published: 03 November 2023
-
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer
Authors (first, second and last of 10)
- Marie Lambert
- Mathieu Alonso
- Etienne Chatelut
- Content type: Short Communication
- Published: 03 October 2023
-
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose
Authors (first, second and last of 7)
- Bart A. Jessen
- Paul Cornwell
- Timothy Hart
- Content type: Correction
- Open Access
- Published: 29 September 2023
-
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
Authors (first, second and last of 6)
- Mototsugu Oya
- Shuichi Kaneko
- Yutaka Okayama
- Content type: Retraction Note
- Open Access
- Published: 16 September 2023
For authors
Submit manuscriptWorking on a manuscript?
Avoid the most common mistakes and prepare your manuscript for journal editors.
Learn more